Bayer submits NDA for radium-223 for CRPC

Bayer AG (Xetra:BAYN) submitted an NDA to FDA for radium-223 dichloride (formerly Alpharadin) to treat castration-resistant prostate cancer (CRPC) in patients with bone metastases. Earlier this week, ...